• Explore /
  • Poster
  • / Randomized phase III trial in MMR deficient (MMRd) endometrial cancer (EC) patients comparing chemotherapy (CT) alone versus dostarlimab in first line advanced/metastatic setting: DOMENICA study (GINECO-EN105b/ENGOT-en13 study).

Randomized phase III trial in MMR deficient (MMRd) endometrial cancer (EC) patients comparing chemotherapy (CT) alone versus dostarlimab in first line advanced/metastatic setting: DOMENICA study (GINECO-EN105b/ENGOT-en13 study).

Abstract Poster

Authors

null

Florence Joly

Centre François Baclesse, Caen and GINECO, Paris, France

Florence Joly , Isabelle Laure Ray-Coquard , Maria Jesus Rubio , Xavier Paoletti , Alison J. Davis , Emma Hudson , Domenica Lorusso , Germana Tognon , Ursula Hasler-Strub , Chel Hun Choi , Mehmet Ali Vardar , Stephanie Lheureux , Toon Van Gorp , David Shao Peng Tan , Fabian Trillsch , Lauriane Eberst , Céline Lescure , Anne-Claire Hardy-Bessard , Marie Chaix

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Uterine Cancer

Clinical Trial Registration Number

NCT05201547

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr TPS5630)

DOI

10.1200/JCO.2023.41.16_suppl.TPS5630

Abstract #

TPS5630

Poster Bd #

316a

Abstract Disclosures

Similar Posters

First Author: Christian Marth

First Author: Nicoletta Colombo

First Author: Mario Javier Pineda

First Author: Martin Reck